{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:28Z","timestamp":1789726288599,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.amjoto.2019.03.012","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T18:28:47Z","timestamp":1553020127000},"page":"456-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vestibulotoxicity in a patient without renal failure after inhaled tobramycin"],"prefix":"10.1016","volume":"40","author":[{"given":"Adam C.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Eliades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amjoto.2019.03.012_bb0005","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2165\/00003495-199447060-00004","article-title":"Parenteral aminoglycoside therapy. Selection, administration and monitoring","volume":"47","author":"Kumana","year":"1994","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.amjoto.2019.03.012_bb0010","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/ki.1988.83","article-title":"Aminoglycoside nephrotoxicity","volume":"33","author":"Humes","year":"1988","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.amjoto.2019.03.012_bb0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000058305","article-title":"Recent advances in understanding aminoglycoside ototoxicity and its prevention","volume":"7","author":"Wu","year":"2002","journal-title":"Audiol Neurootol"},{"issue":"4","key":"10.1016\/j.amjoto.2019.03.012_bb0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.31.4.594","article-title":"Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis","volume":"31","author":"Pedersen","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.amjoto.2019.03.012_bb0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0030-6665(20)30762-3","article-title":"Aminoglycoside cochlear ototoxicity","volume":"26","author":"Matz","year":"1993","journal-title":"Otolaryngol Clin North Am"},{"issue":"3","key":"10.1016\/j.amjoto.2019.03.012_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.amjoto.2019.03.012_bb0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjoto.2019.03.012_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"issue":"24","key":"10.1016\/j.amjoto.2019.03.012_bb0045","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.amjoto.2019.03.012_bb0050","doi-asserted-by":"crossref","first-page":"114S","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.amjoto.2019.03.012_bb0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.amjoto.2019.03.012_bb0060","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0025-6196(11)62603-7","article-title":"Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency","volume":"79","author":"Edson","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.amjoto.2019.03.012_bb0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.healun.2004.05.008","article-title":"Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient","volume":"24","author":"Ahya","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.amjoto.2019.03.012_bb0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.inf.0000202126.44544.41","article-title":"Inhaled tobramycin-associated hearing loss in an adolescent with renal failure","volume":"25","author":"Patatanian","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.amjoto.2019.03.012_bb0075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ppul.10185","article-title":"Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy","volume":"34","author":"Hoffmann","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.amjoto.2019.03.012_bb0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5414\/CNP66464","article-title":"Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa","volume":"66","author":"Izquierdo","year":"2006","journal-title":"Clin Nephrol"},{"issue":"6","key":"10.1016\/j.amjoto.2019.03.012_bb0085","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1046\/j.1523-1755.2000.00437.x","article-title":"Protection from ototoxicity of intraperitoneal gentamicin in guinea pig","volume":"58","author":"Sinswat","year":"2000","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.amjoto.2019.03.012_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm0496-463","article-title":"Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3","volume":"2","author":"Ernfors","year":"1996","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.amjoto.2019.03.012_bb0095","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/nm1296-1338","article-title":"N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss","volume":"2","author":"Basile","year":"1996","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.amjoto.2019.03.012_bb0100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/hmg\/9.12.1787","article-title":"A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity","volume":"9","author":"Guan","year":"2000","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.amjoto.2019.03.012_bb0105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJMc0806397","article-title":"Prevalence of mitochondrial 1555A\u202f\u2192\u202fG mutation in adults of European descent","volume":"360","author":"Vandebona","year":"2009","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.amjoto.2019.03.012_bb0110","doi-asserted-by":"crossref","first-page":"94S","DOI":"10.1378\/chest.120.3_suppl.94S","article-title":"Formulation of aerosolized therapeutics","volume":"120","author":"Kuhn","year":"2001","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.amjoto.2019.03.012_bb0115","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jac\/22.4.483","article-title":"The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum","volume":"22","author":"Ramphal","year":"1988","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.amjoto.2019.03.012_bb0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/AAC.39.1.34","article-title":"Macromolecular mechanisms of sputum inhibition of tobramycin activity","volume":"39","author":"Hunt","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.amjoto.2019.03.012_bb0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.111.4.955","article-title":"A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group","volume":"111","author":"Eisenberg","year":"1997","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.amjoto.2019.03.012_bb0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1592\/phco.23.4.543.32122","article-title":"Toxic serum trough concentrations after administration of nebulized tobramycin","volume":"23","author":"Kahler","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"1\u20132","key":"10.1016\/j.amjoto.2019.03.012_bb0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.heares.2006.05.008","article-title":"Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic","volume":"226","author":"Chen","year":"2007","journal-title":"Hear Res"},{"issue":"17","key":"10.1016\/j.amjoto.2019.03.012_bb0140","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMc053428","article-title":"Aspirin to prevent gentamicin-induced hearing loss","volume":"354","author":"Sha","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjoto.2019.03.012_bb0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.ki.5002295","article-title":"Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine","volume":"72","author":"Feldman","year":"2007","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.amjoto.2019.03.012_bb0150","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1093\/ndt\/gfr211","article-title":"Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis","volume":"26","author":"Tokgoz","year":"2011","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070919302054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070919302054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:03:17Z","timestamp":1759294997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070919302054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0196070919302054"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2019.03.012","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vestibulotoxicity in a patient without renal failure after inhaled tobramycin","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2019.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}